Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode is combining RNA therapies with an organ-specific lipid nanoparticle delivery system

Lauren Martz, Senior Editor
March 26, 2020 3:09 PM UTC
Updated on Mar 27, 2020 at 1:50 AM UTC

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.

The company was formed through a merger between the original ReCode Therapeutics and TranscripTx Inc. earlier this month. MPM Capital, Vida Ventures, Hunt Technology Ventures and Osage University Partners also participated in the oversubscribed round...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Recode Therapeutics Inc.